重组人脑利钠肽治疗非瓣膜性心脏病心力衰竭的疗效

Efficacy of Recombinant Human Brain Natriuretic Peptide in the Treatment of Heart Failure Caused by Non-valvular Heart Diseases

目的:探讨重组人脑利钠肽治疗非瓣膜性心脏病心力衰竭的疗效及对患者C反应蛋白(CRP)、脑利钠肽(BNP)的影响.方法:选择我院收治的80例非瓣膜性心脏病心力衰竭患者,按随机数字表法分为两组,各40例.对照组采用常规抗心衰治疗,观察组在对照组基础上加用注射用重组人脑利钠肽(1.5μg/kg,ivgtt)治疗,比较两组临床疗效、症状缓解时间、心脏彩超监测结果、BNP、CRP水平及不良反应.结果:观察组总有效率高于对照组,差异有统计学意义(P<0.05);观察组呼吸困难、全身水肿、肺啰音等缓解时间均短于对照组,差异有统计学意义(P<0.05);治疗后,观察组左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)均低于对照组,左心射血分数(LVEF)高于对照组,差异有统计学意义(P<0.05);治疗后,观察组BNP、CRP水平均低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较差异无统计学意义(P>0.05).结论:重组人脑利钠肽治疗非瓣膜性心脏病心力衰竭的疗效显著,可有效促进症状缓解,降低BNP、CRP水平,且安全可靠.

Objective:To investigate the efficacy of recombinant human brain natriuretic peptide in the treatment of heart failure caused by non-valvular heart diseases and its effect on C-reactive protein(CRP)and brain natriuretic peptide(BNP).Methods:80 patients with heart failure caused by non-valvular heart diseases admitted to our hospital were selected and randomly divided into two groups,40 cases each.The patients in the control group were given conventional anti-heart failure treatment,and the patients in the observation group were treated with recombinant human brain natriuretic peptide(1.5μg/kg,ivgtt)on the basis of the control group.The clinical efficacy,the remission time of symptoms,color Doppler ultrasound monitoring results,BNP and CRP levels and adverse reactions were compared between the two groups.Results:The total effective rate in the observation group was higher than that in the control group,and the difference was statistically significant(P<0.05).The remission time of symptoms such as dyspnea,systemic edema and pulmonary vocalization in the observation group was lower than that in the control group,and the differences were statistically significant(P<0.05).After treatment,the left ventricular end-diastolic diameter(LVEDD)and left ventricular end-systolic diameter(LVESD)in the observation group were lower than those in the control group,and the left ventricular ejection fraction(LVEF)was higher than that in the control group,with statistically significant differences(P<0.05).After treatment,the levels of BNP and CRP in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Recombinant human brain natriuretic peptide has a significant therapeutic effect on heart failure caused by non-valvular heart diseases,which can effectively promote symptom remission and reduce BNP and CRP levels,and is safe and reliable.